Artiva holder RA Capital buys 6,522 shares

Entities affiliated with RA Capital Management, L.P., significant stockholders and directors of Artiva Biotherapeutics, Inc., purchased 6,522 shares of common stock on July 13, 2026 at a weighted-average price of $8.94 per share (range $8.89–$8.95).

Rhea-AI Filing Summary

Entities affiliated with RA Capital Management, L.P., significant stockholders and directors of Artiva Biotherapeutics, Inc., purchased 6,522 shares of common stock on July 13, 2026 at a weighted-average price of $8.94 per share (range $8.89–$8.95). Following this indirect purchase, the RA Capital funds reported holding 16,817,543 shares of Artiva common stock. The amendment corrects an earlier Form 4 share count, and notes the shares are held by RA Capital Healthcare Fund, L.P., with the Adviser and related parties disclaiming beneficial ownership except to the extent of their pecuniary interests.

Insider Trade Summary

Net Buyer: 6,522 shares

Net Buy 1 txn

Insider RA CAPITAL MANAGEMENT, L.P., RA Capital Healthcare Fund LP, RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., Kolchinsky Peter, Shah Rajeev M.

Role Director, 10% Owner | Director, 10% Owner | Director | Director | Director, 10% Owner | Director, 10% Owner

Bought 6,522 shs ($58K)

Type	Security	Shares	Price	Value
Purchase	Common Stock F1, F2, F3, F4	6,522	$8.94	$58K

Holdings After Transaction: Common Stock — 16,817,543 shares (Indirect, See footnotes)

Footnotes (4)

1. F1. This Form 4/A amends the Form 4 filed on July 14, 2026 to correct the number of shares purchased, which were reported as 6,552, due to a clerical error.
2. F2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.89 to $8.95 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
3. F3. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
4. F4. Held directly by the Fund.

Key Figures

Shares purchased: 6,522 shares Weighted-average purchase price: $8.94 per share Purchase price range: $8.89–$8.95 per share +1 more

4 metrics

Shares purchased 6,522 shares Common Stock transaction on July 13, 2026

Weighted-average purchase price $8.94 per share Price for 6,522 Common Stock shares bought in multiple trades

Purchase price range $8.89–$8.95 per share Range of prices across multiple July 13, 2026 transactions

Indirect holdings after purchase 16,817,543 shares Artiva Common Stock held following the reported transaction

Key Terms

weighted average price, beneficial ownership, pecuniary interest, separately managed account

4 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

beneficial ownership financial

"disclaim beneficial ownership of any of the reported securities, except to the extent"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest financial

"disclaim beneficial ownership... except to the extent of their pecuniary interest therein."

separately managed account financial

"and a separately managed account (the "Account")."

A separately managed account (SMA) is a personalized investment portfolio owned by a single investor and run by a professional manager who buys and sells securities on that investor’s behalf. It matters to investors because an SMA offers tailored asset selection, tax handling, and transparency—like hiring a personal chef who prepares meals to your dietary needs rather than sharing a set menu—so you can align holdings with your goals and see exactly what you own.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RA Capital report for ARTV in this Form 4/A?

RA Capital-affiliated entities reported purchasing 6,522 shares of Artiva Biotherapeutics (ARTV) common stock on July 13, 2026. The shares were bought indirectly through RA Capital Healthcare Fund, L.P., and are attributed to RA Capital as investment manager with beneficial ownership disclaimed except for pecuniary interests.

At what price did RA Capital’s affiliated fund buy ARTV shares?

The ARTV shares were bought at a weighted-average price of $8.94 per share. Footnotes state the 6,522 shares were purchased in multiple transactions, with individual prices ranging from $8.89 to $8.95, and detailed trade breakdowns are available upon request from the reporting persons.

How many ARTV shares do RA Capital entities report owning after this transaction?

After the July 13, 2026 purchase, RA Capital-related entities reported indirect ownership of 16,817,543 shares of Artiva common stock. These shares are held directly by RA Capital Healthcare Fund, L.P., while RA Capital Management, L.P. and related parties report interests through their roles as investment manager and general partner.

Why was this Artiva Biotherapeutics (ARTV) Form 4/A filed as an amendment?

The Form 4/A was filed to correct a clerical error in the prior Form 4. The original filing reported 6,552 shares purchased; this amendment clarifies the correct amount is 6,522 shares, with all other transaction details, including the weighted-average price range, remaining as previously described.

Who is considered to hold the ARTV shares and what do the reporting persons disclaim?

The ARTV shares are held directly by RA Capital Healthcare Fund, L.P., with RA Capital Management, L.P. acting as investment manager. The Adviser, its general partner, the funds, and individuals Peter Kolchinsky and Rajeev Shah disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.

Was RA Capital’s ARTV trade reported under a Rule 10b5-1 trading plan?

The filing indicates the transaction was not reported under a Rule 10b5-1 trading plan. The document-level Rule 10b5-1 checkbox is unchecked, and the footnotes do not describe any pre-arranged trading plan governing this July 13, 2026 purchase of Artiva common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/23/2026 - 09:21 PM Accepted by SEC EDGAR 07/23/2026 - 09:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

RA CAPITAL MANAGEMENT, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Artiva Biotherapeutics, Inc. [ ARTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/14/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/13/2026		P		6,522(1)	A	$8.94(2)	16,817,543	I	See footnotes(3)(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

RA CAPITAL MANAGEMENT, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

RA Capital Healthcare Fund LP

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

RA Capital Nexus Fund, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

RA Capital Nexus Fund III, L.P.

(Last) (First) (Middle)

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Kolchinsky Peter

(Last) (First) (Middle)

C/O RA CAPITAL MANAGEMENT, L.P.

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Shah Rajeev M.

(Last) (First) (Middle)

C/O RA CAPITAL MANAGEMENT, L.P.

200 BERKELEY STREET, 18TH FLOOR

(Street)

BOSTON MASSACHUSETTS 02116

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. This Form 4/A amends the Form 4 filed on July 14, 2026 to correct the number of shares purchased, which were reported as 6,552, due to a clerical error.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.89 to $8.95 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

3. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.

4. Held directly by the Fund.

	/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.	07/23/2026
	/s/ Peter Kolchinsky, Manager of RA Capital Healthcare Fund GP, LLC, the General Partner of RA Capital Healthcare Fund, L.P.	07/23/2026
	/s/ Peter Kolchinsky, Manager of RA Capital Nexus Fund GP, LLC, the General Partner of RA Capital Nexus Fund, L.P.	07/23/2026
	/s/ Peter Kolchinsky, Manager of RA Capital Nexus Fund III GP, LLC, the General Partner of RA Capital Nexus Fund III, L.P.	07/23/2026
	/s/ Peter Kolchinsky, individually	07/23/2026
	/s/ Rajeev Shah, individually	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)